Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

2004 • 1,574 citations

The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature

2002 • 1,208 citations

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

2001 • 1,175 citations

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1997 • 648 citations

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1998 • 625 citations

Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

2000 • 593 citations

Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

2001 • 566 citations

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

1995 • 519 citations

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

2001 • 500 citations

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1995 • 476 citations

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1993 • 421 citations

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

2003 • 415 citations

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

2000 • 373 citations

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

2001 • 357 citations

Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer

2000 • 340 citations

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

2004 • 322 citations

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.

1997 • 299 citations

Antineoplastic Therapy???Induced Palmar Plantar Erythrodysesthesia (???Hand-Foot???) Syndrome

2000 • 279 citations

Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer

2004 • 244 citations

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.

1995 • 243 citations

Advantages of liposomal delivery systems for anthracyclines

2004 • 234 citations

Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy

1995 • 229 citations

Skin Toxic Effects of Polyethylene Glycol–Coated Liposomal Doxorubicin

2000 • 216 citations

Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma

2003 • 215 citations

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicinVersus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group)

1985 • 203 citations

ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES

2002 • 200 citations

Radiofrequency Ablation of Hepatic Tumors: Increased Tumor Destruction with Adjuvant Liposomal Doxorubicin Therapy

2002 • 192 citations

Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma

2004 • 190 citations

Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non–Small-Cell Lung Cancer and Head and Neck Cancer

1999 • 189 citations

Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS

1994 • 187 citations

Hypersensitivity Reactions to Chemotherapeutic Drugs

2003 • 179 citations

Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies

2004 • 179 citations

Unbedenklichkeitsaspekte bei der Anwendung von pegyliertem liposomalem Doxorubicin bei Krebspatienten

1997 • 179 citations

Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis?

1998 • 173 citations

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.

1994 • 170 citations

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma

2003 • 164 citations

A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.

1990 • 163 citations

Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group Study

2002 • 162 citations

Cardiac safety of liposomal anthracyclines

2004 • 160 citations

Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the Peritoneum

2000 • 159 citations

Use of liposomal anthracyclines in Kaposi’s sarcoma

2004 • 150 citations

Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin

2001 • 145 citations

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

1993 • 137 citations

Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.

1998 • 124 citations

Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study

1989 • 123 citations

Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin

1989 • 123 citations

High Intratumoral Accumulation of Stealth Liposomal Doxorubicin in Sarcomas: Rationale for Combination with Radiotherapy

2000 • 115 citations

The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian Cancer

2001 • 113 citations

Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent Dosages

2001 • 112 citations

Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma

1993 • 112 citations

Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma^*

2003 • 111 citations

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

1999 • 105 citations

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer

2002 • 104 citations

Systemic therapy for hepatocellular carcinoma

2001 • 100 citations

Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.

2002 • 99 citations

A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma

2000 • 95 citations

Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.

2002 • 94 citations

Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome

2001 • 88 citations

Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma.

1994 • 86 citations

Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer

2000 • 85 citations

Capecitabine

2003 • 83 citations

Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)

1994 • 80 citations

Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas

1990 • 79 citations

Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors

2001 • 77 citations

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer

2004 • 77 citations

Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer

2001 • 77 citations

Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme

2004 • 74 citations

A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer

1989 • 74 citations

Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial.

2002 • 72 citations

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

2002 • 70 citations

A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas

1998 • 67 citations

Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer

1999 • 66 citations

Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer

2000 • 65 citations

Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs

1999 • 64 citations

Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil???)

1998 • 63 citations

Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin

2002 • 63 citations

Phase I Study of Stealth Liposomal Doxorubicin in Combination With Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer

2001 • 61 citations

Chemotherapy for advanced sarcoma: therapeutic decisions and modalities.

1997 • 60 citations

Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck

2001 • 60 citations

Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies

2004 • 59 citations

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

2003 • 58 citations

Phase II Study of Liposomal Doxorubicin in Advanced Gynecologic Cancers

2000 • 57 citations

Concurrent administration of Docetaxel and Stealth® liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection

2002 • 57 citations

Clinical evaluation of long-term, continuous-infusion doxorubicin.

1983 • 54 citations

A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma

2001 • 54 citations

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

2001 • 53 citations

Caelyx™ in malignant mesothelioma: A phase II EORTC study

2000 • 53 citations

Anthracyclines in the Treatment of Gynecologic Malignancies

2002 • 53 citations

Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast Cancer

2002 • 51 citations

Phase I study of liposomal daunorubicin in patients with acute leukemia

1999 • 51 citations

LIPOSOMAL DAUNORUBICIN (DAUNOXOME) IN CHILDREN WITH RECURRENT OR PROGRESSIVE BRAIN TUMORS

1999 • 50 citations

Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer

2000 • 49 citations

Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin

1993 • 49 citations

Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).

2000 • 48 citations

Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.

1999 • 48 citations

Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up

2001 • 47 citations

Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers

2005 • 47 citations

Phase II Trial of Liposomal Doxorubicin (Doxil®) in Advanced Soft Tissue Sarcomas

2000 • 47 citations

The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma1

2004 • 47 citations

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

2003 • 46 citations

Phase I study of Doxil and vinorelbine in metastatic breast cancer

1999 • 46 citations

Liposomal anthracycline treatment for ovarian cancer

2004 • 46 citations

Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer

2002 • 45 citations

A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma

2003 • 45 citations

Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.

2001 • 45 citations

Chemotherapy for advanced prostate cancer

2005 • 43 citations

Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I–II study

2002 • 42 citations

Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion

1997 • 40 citations

Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study.

2002 • 39 citations

Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment.

1993 • 37 citations

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer

2002 • 36 citations

Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.

1997 • 36 citations

Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors

2002 • 35 citations

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma

2001 • 35 citations

Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma

2002 • 34 citations

Liposomal Doxorubicin (Caelyx R ) in Symptomatic Androgen-independent Prostate Cancer (AIPC): Delayed Response and Flare Phenomenon Should be Considered

2002 • 33 citations

Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma

1997 • 33 citations

Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Mesothelioma

2002 • 33 citations

A Phase II Trial of DaunoXome, Liposome- Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon

1994 • 33 citations

Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia

2002 • 33 citations

Preclinical Studies with Doxorubicin Encapsulated in Polyethyleneglycol-Coated Liposomes

1993 • 32 citations

Liposomal doxorubicin (Doxil®)

1996 • 31 citations

Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma.

2002 • 31 citations

Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs

1999 • 30 citations

Liposomal Doxorubicin for the Treatment of Hormone-Refractory Prostate Cancer

2002 • 30 citations

Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer

2003 • 29 citations

Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial

2002 • 28 citations

Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors.

2003 • 28 citations

Phase II study of pegylated liposomal doxorubicin: Inactive in recurrent small-cell lung cancer

2000 • 28 citations

Role of liposomal anthracyclines in the treatment of multiple myeloma

2004 • 27 citations

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma

1994 • 27 citations

High-dose daunorubicin as liposomal compound (Daunoxome®) in elderly patients with acute lymphoblastic leukemia1

2003 • 27 citations

A Phase I Study of Liposomal Doxorubicin (Doxil) With Topotecan

2000 • 27 citations

Phase II Study of Liposomal Doxorubicin in Patients With Advanced Colorectal Cancer

2001 • 27 citations

Novel strategies for systemic treatment of endometrial cancer

2000 • 26 citations

A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer

1993 • 26 citations

Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment

2003 • 26 citations

Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma

2003 • 26 citations

A Phase II Study of CaelyxTM (Liposomal Doxorubicin) in Metastatic Carcinoma of the Prostate: Tolerability and Efficacy Modification by Liposomal Encapsulation

2002 • 25 citations

A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer.

2003 • 24 citations

A phase I clinical evaluation of liposome-entrapped doxorubicin (Lip-Dox) in patients with primary and metastatic hepatic malignancy

1992 • 24 citations

Palmar‐Plantar Erythrodysesthesia Syndrome Associated with Liposomal Daunorubicin

2000 • 24 citations

Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study

2000 • 23 citations

A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin.

1987 • 23 citations

Phase I Study of Gemcitabine and Liposomal Doxorubicin in Relapsed Ovarian Cancer

2002 • 23 citations

Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer

2003 • 23 citations

Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia

2003 • 21 citations

Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors

2001 • 21 citations

Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract

2003 • 21 citations

Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix

2001 • 21 citations

Radiation recall dermatitis induced by pegylated liposomal doxorubicin

2003 • 20 citations

A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL

2000 • 20 citations

Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes

1999 • 20 citations

A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC)

2004 • 19 citations

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin’s lymphoma

2001 • 19 citations

Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours

2002 • 19 citations

Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Renal Cell Cancer

2002 • 19 citations

A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer

2002 • 18 citations

A phase II study of DaunoXome® in advanced urothelial transitional cell carcinoma

1998 • 17 citations

A phase II trial of Doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma

1995 • 17 citations

Pegylated Doxorubicin for Primary Cutaneous T Cell Lymphoma

2001 • 17 citations

A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer

2001 • 16 citations

Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer

2003 • 16 citations

An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer

2003 • 15 citations

Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors

1999 • 14 citations

Liposomal Daunorubicin (Daunoxome) in Combination with Cyclophosphamide, Vincristine and Prednisolone (COP-X) as Salvage Therapy in Poor-Prognosis Non-Hodgkins Lymphoma

2001 • 14 citations

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

2002 • 14 citations

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies

2003 • 14 citations

Pegylated Liposomal Doxorubicin as Single-Agent Treatment of Low-Grade Non-Hodgkin's Lymphoma: A Phase II Multicenter Study

2003 • 14 citations

Regression of metastatic angiosarcoma of the skin after systemic treatment with liposome-encapsulated doxorubicin and interferon-alpha.

1999 • 13 citations

Phase I Study of Weekly Liposome-Encapsulated Doxorubicin in Patients With Advanced, Androgen-Independent Prostate Cancer

2004 • 13 citations

Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors

2004 • 13 citations

Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies

2005 • 13 citations

Phase I study of liposomal annamycin

2000 • 13 citations

Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis.

2000 • 12 citations

Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: A review

1988 • 12 citations

157 Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer

2003 • 12 citations

A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor

2004 • 12 citations

A Phase I Study of Pegylated Liposomal Doxorubicin Hydrochloride (Caelyx™) in Combination with Cyclophosphamide and Vincristine as Second-Line Treatment of Patients with Small-Cell Lung Cancer

2003 • 12 citations

A Phase I Trial of Prolonged Oral Etoposide and Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study

2002 • 11 citations

Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer

2004 • 11 citations

Doxil (D), vincristine (V), decadron (d) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma [abstract]

2002 • 11 citations

Anthacyclines in non-small cell lung cancer

2001 • 9 citations

The role of chemotherapy in prostate cancer. Minireview.

2000 • 8 citations

A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC)

2004 • 7 citations

Efficacy and Toxicity of Liposomal Daunorubicin Included in PVABEC Regimen for Aggressive NHL of the Elderly

2003 • 7 citations

The role of chemotherapy in prostate cancer

2003 • 6 citations

Anthracyclines in non-small-cell lung cancer: Do they have a therapeutic role?

1999 • 5 citations

Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma

2004 • 5 citations

Phase I Study of Doxil® and Vinorelbine in Patients with Advanced Malignancies

2004 • 5 citations

Untitled

1999 • 5 citations

Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study

2004 • 4 citations

Pegylated liposomal doxorubicin plus temozolamide in the salvage treatment of brain metastases: The update

2004 • 4 citations

Adjuvant chemotherapy with temozolomide and liposomal doxorubicin in the first-line therapy of patients with glioblastoma: A phase-II trial

2005 • 3 citations

A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin’s lymphoma

2005 • 3 citations

Phase 1–2a dose ranging study of TLK286 (a novel glutathione analog) in combination with liposomal doxorubicin in platinum refractory or resistant ovarian cancer

2004 • 3 citations

A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma

2004 • 2 citations

Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study

2004 • 2 citations

875 A prospectively randomized phase II trial of pegylated doxorubicin in hormone refractory prostate cancer

2003 • 2 citations

Cyclophosphamide, liposomal doxorubicin and dexamethasone (CLAD) is safe and efficacious in multiple myeloma

1999 • 1 citations

Adjuvant chemotherapy with temozolomide and pegylated liposomal doxorubicin in the first-line therapy of patients with glioblastoma -a phase-II trial

2004 • 1 citations

Does body mass index predict cutaneous reactions to pegylated liposomal doxorubicin?

2004 • 1 citations

Deleted Work

1955 • 0 citations